文献速递帕金森病与运动障碍

鞘内巴氯芬治疗严重运动障碍型脑瘫:IDYS试验

The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial.
PubMed 文献 · Ann Neurol · 2019-05-21

结果显示鞘内巴氯芬组GAS T评分均值38.9,安慰剂组21.0,组间差异显著,且不良事件数量与类型相似。

要点

  • 鞘内巴氯芬治疗3个月在达成个体治疗目标方面优于安慰剂。
  • GAS T评分组间回归系数为17.8(95%CI 10.4-25.0,p<0.001)。
  • 两组(严重)不良事件的数量和类型相似。

核心结论

  • 鞘内巴氯芬治疗在严重运动障碍型脑瘫患者中达成治疗目标方面优于安慰剂。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,在荷兰2个大学医学中心进行。
  • 按2:2区组随机分配接受鞘内巴氯芬或安慰剂治疗3个月,通过植入式微输注泵给药。
  • 主要结局为个体治疗目标的目标达成量表T评分(GAS T score),采用线性回归模型并以研究中心为协变量。
  • 最终分析纳入鞘内巴氯芬组17例和安慰剂组16例。

主要发现

  • 3个月时GAS T评分均值(标准差)鞘内巴氯芬组为38.9(13.2),安慰剂组为21.0(4.6)。
  • 回归系数为17.8(95%CI 10.4-25.0,p<0.001),支持鞘内巴氯芬优于安慰剂。
  • 两组(严重)不良事件的数量和类型相似。

临床怎么用

  • 对于严重运动障碍型脑瘫(GMFCS IV-V级)且适合鞘内巴氯芬治疗的患者,可考虑鞘内巴氯芬以改善个体治疗目标的达成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intrathecal baclofen treatment is used for the treatment of dystonia in patients with severe dyskinetic cerebral palsy; however, the current level of evidence for the effect is low. The primary aim of this study was to provide evidence for the effect of intrathecal baclofen treatment on individual goals in patients with severe dyskinetic cerebral palsy. METHODS: This multicenter, randomized, double-blind, placebo-controlled trial was performed at 2 university medical centers in the Netherlands. Patients with severe dyskinetic cerebral palsy (Gross Motor Functioning Classification System level IV-V) aged 4 to 24 years who were eligible for intrathecal baclofen were included. Patients were assigned by block randomization (2:2) for treatment with intrathecal baclofen or placebo for 3 months via an implanted microinfusion pump. The primary outcome was goal attainment scaling of individual treatment goals (GAS T score). A linear regression model was used for statistical analysis with study site as a covariate. Safety analyses were done for number and type of (serious) adverse events. RESULTS: Thirty-six patients were recruited from January 1, 2013, to March 31, 2018. Data for final analysis were available for 17 patients in the intrathecal baclofen group and 16 in the placebo group. Mean (standard deviation) GAS T score at 3 months was 38.9 (13.2) for intrathecal baclofen and 21.0 (4.6) for placebo (regression coefficient = 17.8, 95% confidence interval = 10.4-25.0, p < 0.001). Number and types of (serious) adverse events were similar between groups. INTERPRETATION: Intrathecal baclofen treatment is superior to placebo in achieving treatment goals in patients with severe dyskinetic cerebral palsy. ANN NEUROL 2019.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Bonouvrié LA, Becher JG, Vles JSH, et al. The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial. Ann Neurol. 2019. PMID: 31050023. doi:10.1002/ana.25498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。